FDA Reaffirms Retatrutide's Drug Classification | Research Weekly Vol. 17

RESEARCH WEEKLY · VOL. 17

Presented by GEL Labs

Why 40 Amino Acids Matter More Than You Might Think

Sometimes, an enormous regulatory dispute comes down to an extraordinarily small molecular distinction. That's exactly what's happening with retatrutide, the investigational triple-receptor agonist being developed by Eli Lilly.

On October 2, 2026, the U.S. Food and Drug Administration issued a new decision reaffirming its position that retatrutide should be regulated as a drug rather than a biological product. The decision was filed with the U.S. Court of Appeals on October 8 as part of an ongoing legal dispute between Lilly and FDA.

At the center of the disagreement?

How many amino acids does retatrutide actually contain—and which ones count?

It sounds like an unusually technical question.

But the answer affects which regulatory pathway the investigational compound must follow, how future competing products could be evaluated, and what type of market exclusivity might eventually apply.

FDA classifying retatrutide as a drug does not mean FDA has approved it.

Retatrutide remains investigational.

The 40-Amino-Acid Rule

In everyday scientific language, the terms peptide and protein describe related types of molecules. Both consist of amino acids connected through peptide bonds.

But in U.S. pharmaceutical regulation, the distinction has a specific legal significance.

FDA defines a protein for purposes of biological-product classification as an alpha-amino-acid polymer with a defined sequence containing more than 40 amino acids.

That definition matters because products regulated as drugs generally follow the New Drug Application (NDA) pathway, while biological products follow the Biologics License Application (BLA) pathway.

Retatrutide sits directly at the center of that distinction.

And its structure has created two competing interpretations.

The Molecular Disagreement

Retatrutide contains a backbone of 39 alpha amino acids, together with an attached side chain containing additional chemical components.

Lilly has argued that the molecule should be counted as containing 41 amino-acid units when the attached components are included.

FDA takes a different position.

In its October 2 decision, the agency explained that the relevant regulatory definition concerns chains of alpha amino acids connected in a particular way.

FDA concluded that the attached components do not bring retatrutide above the required threshold.

In other words:

• Lilly's position: The molecule qualifies for classification as a biological product.
• FDA's position: Retatrutide does not meet the definition of a protein and does not qualify as a product analogous to a protein.

FDA therefore reaffirmed that an application for retatrutide belongs under the drug-approval provisions of the Federal Food, Drug, and Cosmetic Act.

Read FDA's October 2 decision (PDF)

What makes this dispute especially interesting is that both positions concern the same molecule.

The disagreement is over how its structure fits into the regulatory definitions.

How Did the Dispute Get Here?

This disagreement did not begin last week.

In 2024, Lilly challenged FDA's initial determination that retatrutide was a drug rather than a biological product.

In September 2025, a federal district court agreed with FDA's interpretation of the protein-size requirement. However, the court found that FDA had not adequately explained why retatrutide could not qualify as a product analogous to a protein.

The court sent that question back to the agency for further consideration.

On October 2, 2026, FDA responded.

The agency identified two characteristics it considers necessary for a substance to qualify as analogous to a protein:

1. A defined amino-acid sequence.
2. A sufficient chain length exceeding 40 alpha amino acids.

FDA concluded that retatrutide met the sequence requirement but not the size requirement.

The result was the same classification: a drug, not a biological product.

Read the federal district court order

Lilly's appeal remains unresolved.

The distinction is important: FDA has issued its reconsidered decision, but that does not mean the broader legal dispute has been settled.

Why Does Drug vs. Biologic Classification Matter?

This is much more than a disagreement over terminology.

The classification determines which regulatory application pathway a pharmaceutical manufacturer must follow.

• New Drug Application (NDA): Generally used for products regulated as drugs.
• Biologics License Application (BLA): Generally used for products regulated as biological products.

The pathways also have different regulatory frameworks governing future competing products.

For example, eligible new chemical entities may receive five years of regulatory exclusivity, while qualifying reference biological products generally receive 12 years before biosimilar approval.

Those protections depend on the applicable statutory requirements.

Lilly has continued planning a regulatory submission for retatrutide, previously identifying a BLA submission during the first quarter of 2027.

FDA's latest classification decision points toward the NDA pathway instead.

That explains why the distinction matters.

But it also raises a broader scientific question:

At what point does a peptide become a protein?

There is no single universally applied amino-acid cutoff across every scientific context.

For U.S. biological-product classification, however, FDA has established a specific regulatory definition.

And retatrutide shows just how consequential that definition can become.

The Takeaway

The October 2 FDA decision illustrates something fundamental about peptide science:

Molecular identity and regulatory identity are related, but they are not the same thing.

A molecule can clearly be a peptide from a chemical perspective while its legal classification depends on specialized regulatory definitions.

Retatrutide is a particularly interesting example because its backbone, attached chemical components, and amino-acid counting have become the subject of a federal legal dispute.

FDA has reaffirmed its position.

Lilly continues to challenge that position.

And the compound remains investigational.

Sometimes, understanding the science means understanding the rules used to classify it.

Research Use Only

GEL Labs research products are intended strictly for laboratory and analytical research use only.

Not for human or animal use or consumption. Not a drug, food, cosmetic, or pharmaceutical ingredient intended for compounding.

Scientific, clinical, and regulatory information presented in Research Weekly is provided for educational and research-reference purposes only.

Discussion of Eli Lilly's investigational pharmaceutical, clinical-trial findings, or FDA regulatory proceedings does not imply that GEL Labs research materials are the same as the materials studied in clinical trials or are suitable for human or animal use.

Research References

U.S. Food and Drug Administration.
Decision on Issues Remanded to FDA — Eli Lilly and Company v. Robert F. Kennedy Jr., et al.
October 2, 2026. Filed October 8, 2026.
Read the FDA decision (PDF)

U.S. District Court, Southern District of Indiana.
Eli Lilly and Company v. Becerra, et al. — Amended Order on Cross-Motions for Summary Judgment.
October 2025.
Read the court order

Jastreboff AM, et al.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.
New England Journal of Medicine. 2023.
PubMed — PMID: 37366315

Bellido V, et al.
Retatrutide in Adults With Obesity and Type 2 Diabetes (TRIUMPH-2): A Randomised, Placebo-Controlled Phase 3 Trial.
The Lancet. 2026.
PubMed — PMID: 42810372

U.S. Food and Drug Administration.
FDA's Concerns With Unapproved GLP-1 Drugs Used for Weight Loss.
FDA regulatory information

Editorial note: The regulatory discussion reflects the FDA decision dated October 2, 2026, and the available court record through October 14, 2026. The legal proceedings remain ongoing.